Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Kairos Pharma, Ltd. (KAPA) had Normalized Pre-Tax Income of $-2.60M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-2.60M |
|
-- |
|
-- |
|
$2.34M |
|
$-2.34M |
|
$-0.26M |
|
$-2.60M |
|
|
Normalized Pre-Tax Income |
$-2.60M |
$-2.60M |
|
$-2.60M |
|
$-2.60M |
|
$-2.60M |
|
$-2.34M |
|
$-2.03M |
|
11.36M |
|
11.36M |
|
$-0.23 |
|
$-0.23 |
|
| Balance Sheet Financials | |
$4.17M |
|
-- |
|
$1.60M |
|
$5.77M |
|
$0.99M |
|
-- |
|
-- |
|
$0.99M |
|
$4.78M |
|
$4.55M |
|
$4.78M |
|
13.74M |
|
| Cash Flow Statement Financials | |
$-3.96M |
|
-- |
|
$5.13M |
|
$0.09M |
|
$1.27M |
|
$1.18M |
|
$0.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.96M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-54.50% |
|
-57.16% |
|
-45.13% |
|
-54.50% |
|
$0.35 |
|
$-0.35 |
|
$-0.35 |
|